WO1993010742A2 - Chemical compounds, their preparation and use - Google Patents

Chemical compounds, their preparation and use Download PDF

Info

Publication number
WO1993010742A2
WO1993010742A2 PCT/DK1992/000348 DK9200348W WO9310742A2 WO 1993010742 A2 WO1993010742 A2 WO 1993010742A2 DK 9200348 W DK9200348 W DK 9200348W WO 9310742 A2 WO9310742 A2 WO 9310742A2
Authority
WO
WIPO (PCT)
Prior art keywords
fluoro
piperidine
benzisoxazol
compound
propyl
Prior art date
Application number
PCT/DK1992/000348
Other languages
French (fr)
Other versions
WO1993010742A3 (en
Inventor
John Bondo Hansen
Lone Jeppesen
Frederick Christian GRØNVALD
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK71092A external-priority patent/DK71092D0/en
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to JP5509722A priority Critical patent/JPH07502268A/en
Priority to EP92924586A priority patent/EP0679085A1/en
Priority to AU30817/92A priority patent/AU672182B2/en
Publication of WO1993010742A2 publication Critical patent/WO1993010742A2/en
Publication of WO1993010742A3 publication Critical patent/WO1993010742A3/en
Priority to NO941965A priority patent/NO300684B1/en
Priority to FI942468A priority patent/FI942468A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • DA dopamine
  • clozapine some neuroleptics (e.g. clozapine) show an atypical profile: the compounds are not only beneficial in treating patients, who respond poorly to classical neuroleptic therapy, but the compounds are also relatively devoid of extrapyrimidal side effects (EPS) commonly seen with classical neuroleptics (Ereshefsky et al., Clin.Pharm 8, 691-709, 1989).
  • EPS extrapyrimidal side effects
  • the antipsychotic effect of clozapine and related compounds might be due to its blockade of not only DA-receptors (D-1 , D-2, D-3, D-4) but also 5HT-receptor subtypes (5HT 2 -, 5HT 3 -, 5HT 1C -, 5HT 1A -), NA-c ⁇ -receptors, histamine and possibly other receptors.
  • 5HT 2 -blockade may also be important (Meltzer, Schizphr. Bull. 17: 263-87, 1991) to counteract the socalled negative symptoms of psycho ⁇ sis (delusions and social withdrawal) which are otherwise difficult to treat with conventional neuroleptics.
  • 5HT 2 -antagonists such as naftidrofuryl (Brain Res. 1989, 494(2) 387-90)
  • naftidrofuryl Brain Res. 1989, 494(2) 387-90
  • Ritanserin which is a potent and selective 5HT 2 -antagonist, has been shown to have anxiolytic-antidepressant activities in humans (Barone et al., Drug Gin. Pharm., 20 770 (1986)).
  • serotonergic mechanisms are described to be involved as active factors, or inducing processes, in the organization of sleep (Neuropharmacology, 19, 163 (1980)).
  • the piperidine derivative ketanserine which is a 5HT 2 -antagonist with weak a -blocking properties has been shown to be useful for treatment of various cardiovascular disorders.
  • This invention relates to piperidine derivatives, methods for making them and pharmaceutical compositions containing them.
  • the compounds of this invention demonstrate high affinity for various receptor subtypes including the 5HT 2 -, the NA- ⁇ ,-, the dopamine D and D 2 - receptors or a combination of these.
  • This invention relates to the use of said compounds as medicaments useful for treating CNS-system, cardio ⁇ vascular system and gastrointestinal disorders, such as treatment of anxiety, sleep disorders, depression, psychosis, schizophrenia, migraine, ischemic neuronal damage, asthma, hypertension, urticaria, analgesia and emesis.
  • the present invention provides piperidine derivatives of formula I:
  • R 3 , R 4 , R 5 and R 6 independently are hydrogen, halogen or C ⁇ - alkyl
  • B is -O- or -NH-
  • X is -0- or -NH-
  • Z is hydrogen, C ⁇ -alkyl or -CN
  • R 2 is selected from the group consisting of
  • R , R , R and R 1U independently are hydrogen, C ⁇ -alky!, halogen, C ⁇ -alkoxy or perhalomethyl;
  • -D- represents a 5- or 6-membered heterocycle containing one or more N-, 0- or S-atoms, or a pharmaceutically acceptable salt thereof.
  • the purified reaction product may be converted into a physiologically acceptable salt.
  • Such salts include acid addition salts formed with inorganic or organic acids, for example hydrochlorides, hydrobromides, sulphates, nitrates, oxalates, phosphates, tartrates, citrates, fumarates, maleates, succinates, and sulphonates e.g. mesylates. If desirable, selected salts may be subjected to further purification by recrystallization.
  • the invention includes within its scope all optical isomers of compounds of the general formula I and their mixtures including racemic mixtures thereof.
  • an isocyanate or isothiocyanate of 3,4,5-trimethoxybenzene prepared by refluxing 3,4,5-trimethoxyaniline and phosgene or thiophos- ge ⁇ e respectively in toluene, may be reacted with the desired piperidine alkylamine or piperidine alkylhydroxy intermediate to obtain the desired urea or carbamate of formula I.
  • the procedure includes reacting a compound of formula IV
  • A, R 1 and R 2 have the meanings set forth above and W is 0 or S, with NH 2 -Z, wherein Z has the meaning set forth above, to form a com- pound of formula I, or
  • R 1 has the meaning set forth above, using standard procedures.
  • the compounds of the present invention were tested for binding to various CNS receptor subtypes as well as for analgesic activity
  • Radioactive-labelled ligand 3 H-Spiroperidol is incubated with isolated cell- membrane fragments at 37°C for a given period of time. Following complet ⁇ ed incubation, the incubate is filtered through GF/B filters which are rinsed following filtration to remove unspecifically adhered radioactivity. As opposed to low-molecular compounds, membrane fragments are not rinsed through the filters, the radioactivity bound to the filters is indicative of the amount of ligand bound specifically as well as nonspecifically to the mem ⁇ branes.
  • Polytron kinematica is rinsed with milli-Q-H 2 0 before and after use.
  • Male Wistar rats, 150-200 g are decapitat ⁇ ed, striatum is removed quickly and weighed (approx. 50 mg). Striatum is transferred to a centrifuging vial containing 10 ml ice-cold D2 buffer.
  • Homo- genization is performed applying polytron kinematica (homogenizer) setting 6 for 20 sec.
  • the homogenizer is rinsed with 10 ml D2 buffer in another centrifuging vial.
  • the 10 ml rinsing buffer is added to the tissue vial. Centri- fugation at 18,000 rpm for 10 min.
  • D2 binding will stand concentrations of up to approx. 20% of these solvents without affecting the binding. Most stock solutions are stable at 4°C, attention is, however, paid to any precipitation, change in colour etc. Test- substance dilutions are always made fresh every day. When weighing out test substances, it is attempted to weigh out approx. 1 mg of substance. Less than 0.8 mg must never be weighed out and only infrequently more than 2 mg (for economy reasons), dependent, however, on conc./assay.
  • test value is given as IC 50 indicating the concentration inhibiting specific binding by 50%.
  • Radioactive-labelled ligand 3 H-Prazosin is incubated with isolated cell- membrane fragments at 25°C for a given period of time. Following complet ⁇ ed incubation, the incubate is filtered through GF/B filters, which are rinsed following filtration to remove unspecifically adhered radioactivity. As op ⁇ posed to low-molecular compounds, membrane fragments are not rinsed through the filters, the radioactivity bound to the filters indicates the amount of ligand bound specifically as well as nonspecifically to the membranes.
  • the homogenizer is rinsed with 10 ml D2 buffer in another centrifuging vial.
  • the 10 ml rinsing buffer is added to the tissue vial. Centrifugation at 18,000 rpm for 12 min. at 4°C. This is repeated once. Final pellet is added to 400 x vol. of same buffer, (ex. 500 mg cortex in 200 ml D2 buffer). Can be stored for 30 min. at 0°C.
  • test value is given as IC ⁇ indicating the concentration inhibiting specific binding by 50%.
  • Radioactive-labelled ligand 3 H-SCH 23390 is incubated with isolated cell- membrane fragments in incubation buffer at 30°C for a given period of time. Following completed incubation, the incubate is filtered through GF/B filters, which are rinsed following filtration to remove unspecifically adhered ra ⁇ dioactivity. As opposed to low-molecular compounds, membrane fragments are not rinsed through the filters, the radioactivity bound to the filters indicates the amount of ligand bound specifically as well as nonspecifically to the membranes.
  • mice Male Wistar rats, 150-200 g are decapitated. Striatum is removed quickly, weighed (approx. 50 mg) and carefully homogenized in 100 x vol. of buffer I applying glass/teflon homogenizer 10 up/down strokes. Ex.: 50 mg striatum is homogenized in 5,000 ⁇ l buffer I. The homogenate is centrifuged at 18,000 rpm for 20 min. at 4°C, and the supernate is decanted. This step is performed three times, and each time the pellet is resuspended and homogenized in 100 x vol. of buffer I. Following the third centrifugation, the pellet is suspended in 100 x vol. of resuspension buffer and homogenized. The tissue is now ready for use. The tissue is stable at 0°C for 8 hours.
  • test value is given as IC ⁇ indicating the concentration inhibiting specific binding by 50%.
  • Radioactive-labelled ligand 3 H-Ketanserine is incubated with isolated cell membrane fragments at 37°C for a given period of time. Following complet ⁇ ed incubation, the incubate is filtered through GF/B filters, which are rinsed following filtration to remove unspecifically adhered radioactivity. As op- posed to low-molecular compounds, membrane fragments are not rinsed • through the filters, the radioactivity bound to the filters indicates the amount of ligand bound specifically as well as nonspecifically to the membranes.
  • the preparation is made in ice bath. Polytron kinematica is rinsed with milli- Q-H 2 0 before and after use. Male Wistar rats, 150-200 g are decapitated. Frontal cortex is removed quickly and weighed (approx. 200 mg). Frontal cortex is added to centrifuging vial containing 10 ml ice-cold D2 buffer. Homogenization applying polytron kinematica (homogenizer) setting 6 for 20 sec. The homogenizer is rinsed with 10 ml D2 buffer in another centrifug- ing vial. The 10 ml rinsing buffer is added to the tissue vial. Centrifuged at 18,000 rpm for 10 min. at 4°C. Final pellet is transferred to 125 x vol. of same buffer. (Ex 200 mg in 25 ml D2 buffer). Can be stored for approx. 30 min. at 0°C.
  • test value is given as IC 50 i.e. the concentration inhibiting specific binding by 50%.
  • mice i.p. injection of acetic acid induces a writhing syndrome which is antagonized by analgesics (Siegmund et al., 1957; Eckhardt et al., 1957).
  • Acetic acid 0.5 per cent is injected i.p. (0.15 ml/10 g body weight) to 6 mice (NMRI, either sex weighing 20-25 g) pretreated with physiological saline (controls) and to 6 mice pretreated with test substance.
  • acetic acid induces a syndrome characterized by contraction of abdomen, turning of trunk and extension of hind limbs.
  • Saline and test substances are administered s.c. 30 min. before acetic acid. The number of writhings is counted 5-15 min. after injection of acetic acid.
  • test substance is equivalent to 5-10 per cent of LD 50 . If this dose decreases writhings, 3-5 dose levels are tested. The activity is expressed as per cent protection:
  • the effect of active substances is evaluated by a dose response curve, log dose on the abscissa, and per cent protection on the ordinate.
  • the potency is expressed as the dose (ED 50 in mg/kg) giving 50 per cent protection against writhings.
  • Analgesics and various other drugs inhibit acetic acid-induced writhings in mice. This test is used as a screening test for analgesics. Additional results from other screening tests are required to exclude active anti-writhing substances without analgesic effect.
  • the compounds of this invention typically binds to NA- ⁇ 5HT 2 -, DA-D , and DA-D 2 -receptors, with IC 50 values in the order of 0.1 nM to 1 ⁇ M. Furthermore the compounds are able to antagonize the acetic acid induced writhing in mice with ED 50 -values typically in the order of 0.1 mg/kg to 100 mg/kg.
  • the compounds of the invention may be placed into the form of pharmaceutical composi ⁇ tions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids, such as solutions, sus ⁇ pensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use.
  • Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additio ⁇ nal active compounds or principles, and such unit dosage forms may contain any suitable effective central nervous system ailment alleviating amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • Tablets containing one (1) milligram of active ingredient or, more broadly, one (1) to thirty (30) milligrams, per • tablet, are accordingly suitable representative unit dosage forms.
  • the compounds of this invention can thus be used for the formulation of pharmaceutical preparations, e.g. for oral and parenteral administration to mammals including humans, in accordance with conventional methods of galenic pharmacy.
  • Conventional excipients are such pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral or oral application which do not deleteriously react with the active compound.
  • Such carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose, amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and digly- cerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvi- nylpyrrolidone.
  • the pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compounds.
  • injectable solutions or suspensions preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
  • Ampoules are convenient unit dosage forms.
  • tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like, the carrier preferably being lactose and/or corn starch and/or potato starch.
  • a syrup, elixir or like can be used when a sweetened vehicle can be employed.
  • the compound of the invention is dis ⁇ claimedd in unit dosage form comprising 0.05-100 mg in a pharmaceutically acceptable carrier per unit dosage.
  • a typical tablet which may be prepared by conventional tabletting tech ⁇ niques contains:
  • Phenylisocyanate (0.36 g, 3 mmol) and 3-[4-(6-fluoro-1 ,2-benzisoxazol-3- yl)piperidino]propanol (0.3 g, 1.1 mmol) was refluxed in toluene (25 ml) for 6 h. The mixture was cooled to room temperature and hydrochloric acid in ether was added. The resulting precipitate was recrystallized from etha- nol/ether and isopropanol/ether to give 180 mg of the title compound as white crystals. M.p. 204.5-205.5°C. MS (70 eV): m/z 397 (39%, M + ), 278 (4), 259 (26), 233 (50), 178 (28), 96 (100).
  • N-cyanodiphenoxyimidocarbonate (1.2 g, 5 mmol), 3,4-methy- lenedioxyaniline (0.7 g, 5 mmol) and 2-propanol (25 ml) was stirred at room temperature for 16 h. The formed precipitate was taken up in methylene chloride, treated with activated carbon. Evaporation of the solute and trituration with ether gave 1.2 g of N-cyano-N'-3,4-methylenedioxyphenyl-0- phenylisourea. M.p. 172-174°C.

Abstract

The present invention relates to therapeutically active piperidine derivatives (I), a method of preparing the same and to pharmaceutical compositions comprising the compounds. The compounds are useful in the treatment of indications related to the CNS-system, cardiovascular system or to gastrointestinal disorders, wherein A represents a straight or branched saturated hydrocarbon chain containing from 2 to 6 carbon atoms, R1 is (II).

Description

Chemical Compounds, their Preparation and Use
Much evidence has accumulated to suggest that neuroleptics exert their antipsychotic action by blocking dopamine (DA) receptors in the brain. In recent years, it has become clear that some neuroleptics (e.g. clozapine) show an atypical profile: the compounds are not only beneficial in treating patients, who respond poorly to classical neuroleptic therapy, but the compounds are also relatively devoid of extrapyrimidal side effects (EPS) commonly seen with classical neuroleptics (Ereshefsky et al., Clin.Pharm 8, 691-709, 1989). In this respect it has been speculated that atypical neuro¬ leptics are working mainly by blocking socalled A10 mesolimbic DA systems (areas which are thought to be affected in psychosis), while the side effects of classical neuroleptics are produced by blockade of DA receptors in the motor areas of the brain (A9 DA system (Gudelsky, Psy- chopharmacology (Berl) 99: S13-S17, 1989)). The antipsychotic effect of clozapine and related compounds might be due to its blockade of not only DA-receptors (D-1 , D-2, D-3, D-4) but also 5HT-receptor subtypes (5HT2-, 5HT3-, 5HT1C-, 5HT1A-), NA-c^ -receptors, histamine and possibly other receptors.
Furthermore, 5HT2-blockade may also be important (Meltzer, Schizphr. Bull. 17: 263-87, 1991) to counteract the socalled negative symptoms of psycho¬ sis (delusions and social withdrawal) which are otherwise difficult to treat with conventional neuroleptics.
Compounds reducing 5-HT neurotransmission have been suggested to be useful for the treatment of various, neurological and psychiatric diseases. 5HT2-antagonists, such as naftidrofuryl (Brain Res. 1989, 494(2) 387-90), are described to exhibit a protective effect on ischemic neuronal damage in the gerbil. Ritanserin, which is a potent and selective 5HT2-antagonist, has been shown to have anxiolytic-antidepressant activities in humans (Barone et al., Drug Gin. Pharm., 20 770 (1986)). Furthermore serotonergic mechanisms are described to be involved as active factors, or inducing processes, in the organization of sleep (Neuropharmacology, 19, 163 (1980)).
The piperidine derivative ketanserine, which is a 5HT2-antagonist with weak a -blocking properties has been shown to be useful for treatment of various cardiovascular disorders.
Other similar piperidine derivatives are described in German Patent 1930818, EP 368388, EP 377528, EP 184258 and EP 402644.
This invention relates to piperidine derivatives, methods for making them and pharmaceutical compositions containing them.
The compounds of this invention demonstrate high affinity for various receptor subtypes including the 5HT2-, the NA-α,-, the dopamine D and D2- receptors or a combination of these. This invention relates to the use of said compounds as medicaments useful for treating CNS-system, cardio¬ vascular system and gastrointestinal disorders, such as treatment of anxiety, sleep disorders, depression, psychosis, schizophrenia, migraine, ischemic neuronal damage, asthma, hypertension, urticaria, analgesia and emesis.
The present invention provides piperidine derivatives of formula I:
(l)
Figure imgf000004_0001
wherein A represents a straight or branched saturated hydrocarbon chain containing from 2 to 6 carbon atoms;
R1 is
Figure imgf000005_0001
wherein R3, R4, R5 and R6 independently are hydrogen, halogen or C^- alkyl;
B is -O- or -NH-;
X is -0- or -NH-
Y is =0, =S or =NZ
wherein Z is hydrogen, C^-alkyl or -CN;
R2 is selected from the group consisting of
Figure imgf000005_0002
wherein R , R , R and R1U independently are hydrogen, C^-alky!, halogen, C^-alkoxy or perhalomethyl;
-D- represents a 5- or 6-membered heterocycle containing one or more N-, 0- or S-atoms, or a pharmaceutically acceptable salt thereof.
The purified reaction product may be converted into a physiologically acceptable salt. Such salts include acid addition salts formed with inorganic or organic acids, for example hydrochlorides, hydrobromides, sulphates, nitrates, oxalates, phosphates, tartrates, citrates, fumarates, maleates, succinates, and sulphonates e.g. mesylates. If desirable, selected salts may be subjected to further purification by recrystallization.
The invention includes within its scope all optical isomers of compounds of the general formula I and their mixtures including racemic mixtures thereof.
Specific compounds within the scope of the present invention include the following, or pharmaceutically acceptable salts thereof:
4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-[3-(6-indazolylcarbamoyloxy)propyl]- piperidine,
4-(6-Fluoro-1,2-benzisoxazoI-3-yl)-1-[3-(5-indazolylcarbamoyloxy)propyl]- piperidine,
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1 -[2-(5-indazolylcarbamoyloxy)ethyI]- piperidine,
4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-[2-(6-indazolylcarbamoyloxy)ethyl]- piperidine,
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1 -[2-(6-(1 -methylindazolyl)carbamoyloxy)- ethyl] piperidine, 4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1 -[2-(5-(1 -methylindazolyl)carbamoyloxy)- ethyljpiperidine,
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1-[3-(6-indolylcarbamoyloxy)propyl]- piperidine,
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1-[2-(6-indolylcarbamoyloxy)ethyl]piperi- dine,
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1 -[3-(5-indolylcarbamoyloxy)propyl]- piperidine,
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1-[2-(5-indolylcarbamoyloxy)ethyl]piperi- dine,
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1 -[2-(5-(1 -methylindolyl)carbamoyloxy)- ethyl] piperidine,
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1 -[3-(5-(1 -methylindolyl)carbamoyloxy)pro- pyl] piperidine,
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1 -[3-(6-(1 -methylindolyl)carbamoyloxy)pro- pyl] piperidine,
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1 -[2-(6-(1 -methylindolyl)carbamoyloxy)- ethyl] piperidine,
1 - [3-(6-Benzoxazolylcarbamoyloxy) propy I] -4- (6-f luoro- 1 ,2-benzisoxazol-3-yl) - piperidine,
1-[2-(6-Benzoxazolylcarbamoyloxy)ethyl]-4-(6-fluoro-1 ,2-benzisoxazol-3- yl)piperidine, 1-[3-(5-Benzoxazolylcarbamoyloxy)propyl]-4-(6-fluoro-1,2-benzisoxazol-3- yl) piperidine,
1-[2-(5-Benzoxazolylcarbamoyloxy)ethyl]-4-(6-fluoro-1,2-benzisoxazol-3- yl) piperidine,
1-[2-(6-BenzothiazolylcarbamoyIoxy) ethyl] -4-(6-fluoro-1 , 2-benzisoxazol-3- y I) piperidine,
1 -[2-(6-Benzothiazolylthiocarbamoyloxy)ethyl]-4-(6-fluoro-1 ,2-benzisoxazol-3- yl) piperidine,
1-[3-(6-Benzothiazolylthiocarbamoyloxy)propyl]-4-(6-fluoro-1,2-benzisoxazol- 3-yl) piperidine,
4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-[3-(6-(2-methylbenzothiazolyl)carbamoyl- oxy) propyl] piperidine,
4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-[2-(6-(2-methylbenzothiazolyl)carbamoyl- oxy)ethyl]piperidine,
1-[3-(5-Benzothiazolylcarbamoyloxy)propyl]-4-(6-fluoro-1,2-benzisoxazol-3- yl) piperidine,
1-[2-(5-Benzothiazolylcarbamoyloxy) ethyl] -4-(6-fluoro-1 ,2-benzisoxazol-3- yl) piperidine,
1-[3-(5-Benzothiazolylthiocarbamoyloxy)propyl]-4-(6-fluoro-1,2-benzisoxazol- 3-yl)piperidine,
1-[2-(5-Benzothiazolylthiocarbamoyloxy)ethyl]-4-(6-fluoro-1,2-benzisoxazol-3- yl)piperϊdine, 4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1-[2-(3,4,5-trimethoxyphenylcarbamoyl- oxy)ethyl] piperidine,
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1-[2-(3,4,5-trimethoxyphenylthiocarbamoyl- oxy) ethyl] piperidine,
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1-[3-(3,4,5-trimethoxyphenylthiocarbamoyl- oxy) propy I] piperidine,
1 -[3-(3,4-Dimethoxyphenylcarbamoyloxy)propyl]-4-(6-fluoro-1 ,2-benzisoxa- zol-3-yl) piperidine,
1 - [2- (3,4-Dimethoxypheny Icarbamoy loxy) ethyl] -4- (6-f luoro- 1 ,2-benzisoxazol- 3-yl) piperidine,
1-[2-(3,4-Dimethoxyphenylthiocarbamoyloxy)ethyl]-4-(6-fluoro-1 ,2-benz- isoxazol-3-yl) piperidine,
1-[3-(3,4-Dimethoxyphenylthiocarbamoyloxy)propyl]-4-(6-fluoro-1 ,2-benz- isoxazol-3-yl)piperidine,
1-[2-(3-Chloro-4-methoxyphenylcarbamoyloxy)ethyl]-4-(6-fiuoro-1 ,2-benz- isoxazol-3-yl)piperidine,
1 -[2-(3-Chloro-4-methoxyphenylthiocarbamoyloxy)ethyl]-4-(6-fluoro-1 ,2- benzisoxazol-3-yl) piperidine,
1-[3-(3-Chloro-4-methoxyphenylthiocarbamoyloxy)propyl]-4-(6-fluoro-1 ,2- benzisoxazol-3-yl) piperidine.
The invention also relates to methods of preparing the above mentioned compounds. These methods include reacting a compound of formula II γ=C=N-R2 (II)
wherein Y and R2 have the meanings set forth above, with a compound of formula III
Figure imgf000010_0001
wherein A, X and R1 have the meanings set forth above to form a com¬ pound of formula I.
For instance an isocyanate or isothiocyanate of 3,4,5-trimethoxybenzene, prepared by refluxing 3,4,5-trimethoxyaniline and phosgene or thiophos- geπe respectively in toluene, may be reacted with the desired piperidine alkylamine or piperidine alkylhydroxy intermediate to obtain the desired urea or carbamate of formula I.
Compounds of formula I, wherein X is -NH- and Y is =NZ wherein Z has the meanings set forth above are prepared by standard procedures as described in e.g. H.J. Petersen et al., J.Med.Chem. (1978) 21, 773-781, and R. Lee Webb et al., J. Heterocyclic Chem. 24, 275 (1987).
The procedure includes reacting a compound of formula IV
Figure imgf000010_0002
(IV) wherein A and R1 have the meanings set forth above, with a compound of formula V
Figure imgf000011_0001
wherein R and Z have the meanings set forth above, or
reacting a compound of formula VI
Figure imgf000011_0002
prepared by standard procedures, from a compound of formula VII
Figure imgf000011_0003
wherein A, R1 and R2 have the meanings set forth above and W is 0 or S, with NH2-Z, wherein Z has the meaning set forth above, to form a com- pound of formula I, or
reacting a compound of formula III, wherein X is -NH- and A and R1 have the meanings set forth above, with a compound of formula VIII
Figure imgf000012_0001
prepared by the method described in R. Lee Webb and C.S. Labaw, J. Heterocyclic Chem. 19, 1205 (1982) from R2-NH2 and N-cyanodiphenoxy- imidocarbonate.
Compounds of formula III, wherein R\ A and X have the meanings set forth above, have been prepared by alkyfating the known piperidine IX (J.T.Strup- czewski et al., J.Med.Chem., 28, 761-769 (1985))
R O-< m (IX)
wherein R1 has the meaning set forth above, using standard procedures.
The compounds of the present invention were tested for binding to various CNS receptor subtypes as well as for analgesic activity |n vitro in mice.
Detailed conditions for the in vitro and in vivo assays are described below:
IN-VITRO inhibition of DOPAMINE D2 receptor binding.
Method description
Principle: Radioactive-labelled ligand 3H-Spiroperidol is incubated with isolated cell- membrane fragments at 37°C for a given period of time. Following complet¬ ed incubation, the incubate is filtered through GF/B filters which are rinsed following filtration to remove unspecifically adhered radioactivity. As opposed to low-molecular compounds, membrane fragments are not rinsed through the filters, the radioactivity bound to the filters is indicative of the amount of ligand bound specifically as well as nonspecifically to the mem¬ branes.
Tissue preparation:
The procedure is performed in ice bath. Polytron kinematica is rinsed with milli-Q-H20 before and after use. Male Wistar rats, 150-200 g are decapitat¬ ed, striatum is removed quickly and weighed (approx. 50 mg). Striatum is transferred to a centrifuging vial containing 10 ml ice-cold D2 buffer. Homo- genization is performed applying polytron kinematica (homogenizer) setting 6 for 20 sec. The homogenizer is rinsed with 10 ml D2 buffer in another centrifuging vial. The 10 ml rinsing buffer is added to the tissue vial. Centri- fugation at 18,000 rpm for 10 min. at 4°C. Final pellet is transferred to 1 ,000 x vol. of same buffer. (Ex. 50 mg striatum in 50 ml D2 buffer). Can be stored at 0°C for at least 4 hours. Note that the tissue must be monoge- neous (uniform) before use. If not, brief homogenization is performed.
Assay:
2,500 μ\ tissue (homogeneous) 25 μl 3H-Spiroperidol (0.05 nM) 25 μl test substance/H20/blind (Domperidone 0.2 μM)
Incubation for 20 min. at 37°C - 10 min. on ice bath.
10 ml ice-cold 0.9% NaCI is added to the tubes and filtered through GF/B filters (use gloves). This procedure is repeated. The filters are placed in counting vials and 4 ml opti-flour is added (perform in fume cupboard, use gloves). Counting is performed at window 0-19 of the beta-counter (Pachard). Note that receptor box and lid are rinsed thoroughly in H20 after use to avoid contamination. Further, the analytical site is cleaned carefully every day after use.
Test substances:
Dissolved in H20, EtOH, MeOH or DMSO and further diluted in H20. The
D2 binding will stand concentrations of up to approx. 20% of these solvents without affecting the binding. Most stock solutions are stable at 4°C, attention is, however, paid to any precipitation, change in colour etc. Test- substance dilutions are always made fresh every day. When weighing out test substances, it is attempted to weigh out approx. 1 mg of substance. Less than 0.8 mg must never be weighed out and only infrequently more than 2 mg (for economy reasons), dependent, however, on conc./assay.
Results:
The test value is given as IC50 indicating the concentration inhibiting specific binding by 50%.
IN-VITRO inhibition of αt.,-receptor binding.
Method description
Principle:
Radioactive-labelled ligand 3H-Prazosin is incubated with isolated cell- membrane fragments at 25°C for a given period of time. Following complet¬ ed incubation, the incubate is filtered through GF/B filters, which are rinsed following filtration to remove unspecifically adhered radioactivity. As op¬ posed to low-molecular compounds, membrane fragments are not rinsed through the filters, the radioactivity bound to the filters indicates the amount of ligand bound specifically as well as nonspecifically to the membranes.
Tissue preparation:
The procedure is performed in ice bath. Polytron kinematica is rinsed with milli-Q-H20 before and after use. Male Wistar rats, 150-200 g are decapitat- ed, cortex is removed quickly and weighed (approx. 500 mg). Cortex is transferred to a centrifuging vial containing 10 ml ice-cold D2 buffer. Homo- genization applying polytron kinematica (homogenizer) setting 6 for 20 sec.
The homogenizer is rinsed with 10 ml D2 buffer in another centrifuging vial.
The 10 ml rinsing buffer is added to the tissue vial. Centrifugation at 18,000 rpm for 12 min. at 4°C. This is repeated once. Final pellet is added to 400 x vol. of same buffer, (ex. 500 mg cortex in 200 ml D2 buffer). Can be stored for 30 min. at 0°C.
Assay:
2,000 μl tissue 25 μl 3H-Prazosin (0.5 nM) 25 μl test substance/H20/blind Phentolamine (10 μM)
Incubation for 30 min. at 25°C.
10 ml of ice-cold 0.9% NaCI is added to the tubes and filtered through GF/B filters (use gloves). This procedure is repeated. Filters are placed in count¬ ing vials and 4 ml opti-flour is added (perform in fume cupboard, use gloves). Counting is performed at window 0-19 of the beta-counter
(Pachard). Note that receptor box and cover are rinsed thoroughly in H20 after use to avoid contamination. Further, the analytical site is cleaned carefully every day after use.
Test substances:
Dissolved in H20, EtOH, MeOH or DMSO and further diluted in H20. The binding will stand concentrations of up to approx. 5% of these solvents without affecting the binding. Most stock solutions are stable at 4°C. Attention is, however, paid to any precipitation, change in colour etc. Test- substance dilutions are always made fresh every day. When weighing out test substances, it is attempted to weigh out approx. 1 mg of substance. Less than 0.8 mg must never be weighed out and only infrequently more than 2 mg (for economy reasons), dependent, however, on conc./assay.
Results:
The test value is given as IC^ indicating the concentration inhibiting specific binding by 50%.
IN-VITRO inhibition of DOPAMINE D1 receptor binding.
Method description
Principle:
Radioactive-labelled ligand 3H-SCH 23390 is incubated with isolated cell- membrane fragments in incubation buffer at 30°C for a given period of time. Following completed incubation, the incubate is filtered through GF/B filters, which are rinsed following filtration to remove unspecifically adhered ra¬ dioactivity. As opposed to low-molecular compounds, membrane fragments are not rinsed through the filters, the radioactivity bound to the filters indicates the amount of ligand bound specifically as well as nonspecifically to the membranes. Tissue preparation:
Male Wistar rats, 150-200 g are decapitated. Striatum is removed quickly, weighed (approx. 50 mg) and carefully homogenized in 100 x vol. of buffer I applying glass/teflon homogenizer 10 up/down strokes. Ex.: 50 mg striatum is homogenized in 5,000 μl buffer I. The homogenate is centrifuged at 18,000 rpm for 20 min. at 4°C, and the supernate is decanted. This step is performed three times, and each time the pellet is resuspended and homogenized in 100 x vol. of buffer I. Following the third centrifugation, the pellet is suspended in 100 x vol. of resuspension buffer and homogenized. The tissue is now ready for use. The tissue is stable at 0°C for 8 hours.
Assay:
600 μl incubation buffer
100 μl 3H-SCH 23390 (0.2 nM)
100 μl tissue
200 μl test substance/H20/blind (cis-flupentixol 2 μM)
Incubation for 60 min. at 30°C.
10 ml of ice-cold 0.9% NaCI is added to the tubes. Filtration is performed through GF/B filters (use gloves). This procedure is repeated. Filters are placed in counting vials and 4 ml opti-flour is added (perform in fume cupboard, use gloves) and counting is performed at window 0-19 of the beta-counter (Pachard). Note that receptor box and lid are rinsed thorough¬ ly in H20 after use to avoid contamination. Further, the analytical site is cleaned carefully every day after use.
Test substances:
Dissolved in H20, EtOH, MeOH or DMSO and further diluted in H~0. The D1 binding will stand concentrations of up to approx. 20% of these solvents without affecting the binding. Most stock solutions are stable at 4°C. Attention should, however, be paid to any precipitation, change in colour etc. Test-substance dilutions are always made fresh every day. When weighing out test substances, it is attempted to weigh out approx. 1 mg of substance. Less than 0.8 mg must never be weighed out and only in¬ frequently more than 2 mg (for economy reasons), dependent, however, on conc./assay.
Results:
The test value is given as IC^ indicating the concentration inhibiting specific binding by 50%.
IN VITRO inhibition of 5HT -receptor binding
Method description
Principle:
Radioactive-labelled ligand 3H-Ketanserine is incubated with isolated cell membrane fragments at 37°C for a given period of time. Following complet¬ ed incubation, the incubate is filtered through GF/B filters, which are rinsed following filtration to remove unspecifically adhered radioactivity. As op- posed to low-molecular compounds, membrane fragments are not rinsed • through the filters, the radioactivity bound to the filters indicates the amount of ligand bound specifically as well as nonspecifically to the membranes.
Tissue preparation:
The preparation is made in ice bath. Polytron kinematica is rinsed with milli- Q-H20 before and after use. Male Wistar rats, 150-200 g are decapitated. Frontal cortex is removed quickly and weighed (approx. 200 mg). Frontal cortex is added to centrifuging vial containing 10 ml ice-cold D2 buffer. Homogenization applying polytron kinematica (homogenizer) setting 6 for 20 sec. The homogenizer is rinsed with 10 ml D2 buffer in another centrifug- ing vial. The 10 ml rinsing buffer is added to the tissue vial. Centrifuged at 18,000 rpm for 10 min. at 4°C. Final pellet is transferred to 125 x vol. of same buffer. (Ex 200 mg in 25 ml D2 buffer). Can be stored for approx. 30 min. at 0°C.
Assay:
1250 μl tissue 25 μl 3H-Ketanserine (0.4 nM) 25 μl test substance/H20/blind cyproheptadine (2 μM)
Incubation for 15 min. at 37°C
10 ml ice-cold 0.9% NaCI is added to the tubes. Filtration is performed through GF/B filters (use gloves). This procedure is repeated. The filters are placed in counting vials and 4 ml opti-flour is added (prepare in fume cupboard, use gloves). Counting at window 0-19 of the beta-counter (Pachard). Note that receptor box and lid are rinsed thoroughly in H20 after use to avoid contamination. Further, the analytical site is cleaned carefully every day.
Test substances:
Dissolved in H20, EtOH, MeOH or DMSO and further diluted in H20. The 5HT2 binding will stand concentrations of up to approx. 5% of these sol- vents without affecting the binding. Most stock solutions are stable at 4°C. Attention should, however, be paid to any precipitation, change in colour etc. Test-substance dilutions are always made fresh every day. When weighing out test substances, it is attempted to weigh out approx. 1 mg of substance. Less than 0.8 mg must never be weighed out and only in¬ frequently more than 2 mg (for economy reasons), dependent, however, on conc./assay.
Results:
The test value is given as IC50 i.e. the concentration inhibiting specific binding by 50%.
Antagonism of acetic acid-induced writhiπgs in mice
Principle:
In mice i.p. injection of acetic acid induces a writhing syndrome which is antagonized by analgesics (Siegmund et al., 1957; Eckhardt et al., 1957).
Method:
Acetic acid 0.5 per cent is injected i.p. (0.15 ml/10 g body weight) to 6 mice (NMRI, either sex weighing 20-25 g) pretreated with physiological saline (controls) and to 6 mice pretreated with test substance. In the controls acetic acid induces a syndrome characterized by contraction of abdomen, turning of trunk and extension of hind limbs. Saline and test substances are administered s.c. 30 min. before acetic acid. The number of writhings is counted 5-15 min. after injection of acetic acid.
Results:
Initially, the dose of test substance is equivalent to 5-10 per cent of LD50. If this dose decreases writhings, 3-5 dose levels are tested. The activity is expressed as per cent protection:
■i 00 . a erage writhings of treated group x 100 average writhings of daily control groups
The effect of active substances is evaluated by a dose response curve, log dose on the abscissa, and per cent protection on the ordinate. The potency is expressed as the dose (ED50 in mg/kg) giving 50 per cent protection against writhings.
Specificity of test:
Analgesics and various other drugs inhibit acetic acid-induced writhings in mice. This test is used as a screening test for analgesics. Additional results from other screening tests are required to exclude active anti-writhing substances without analgesic effect.
References:
Eckhardt, E. et al.
Ethioiogy of chemically induced writhing in mouse and rat. Proc. Soc. exp. Biol. 98, 186-188, 1958.
Siegmund, E. et al. A method for evaluating both non-narcotic and narcotic analgesics. Proc. Soc. exp. Biol. 95, 729-731 , 1957.
The compounds of this invention typically binds to NA- ^ 5HT2-, DA-D , and DA-D2-receptors, with IC50 values in the order of 0.1 nM to 1 μM. Furthermore the compounds are able to antagonize the acetic acid induced writhing in mice with ED50-values typically in the order of 0.1 mg/kg to 100 mg/kg. The compounds of the invention, together with a conventional adjuvant, carrier, or diluent, and if desired a pharmaceutically acceptable acid addi¬ tion salt thereof, may be placed into the form of pharmaceutical composi¬ tions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids, such as solutions, sus¬ pensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additio¬ nal active compounds or principles, and such unit dosage forms may contain any suitable effective central nervous system ailment alleviating amount of the active ingredient commensurate with the intended daily dosage range to be employed. Tablets containing one (1) milligram of active ingredient or, more broadly, one (1) to thirty (30) milligrams, per • tablet, are accordingly suitable representative unit dosage forms.
The compounds of this invention can thus be used for the formulation of pharmaceutical preparations, e.g. for oral and parenteral administration to mammals including humans, in accordance with conventional methods of galenic pharmacy.
Conventional excipients are such pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral or oral application which do not deleteriously react with the active compound.
Examples of such carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose, amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and digly- cerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvi- nylpyrrolidone. The pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compounds.
For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
Ampoules are convenient unit dosage forms.
For oral application, particularly suitable are tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like, the carrier preferably being lactose and/or corn starch and/or potato starch. A syrup, elixir or like can be used when a sweetened vehicle can be employed. Generally, as to broader ranges, the compound of the invention is dis¬ pensed in unit dosage form comprising 0.05-100 mg in a pharmaceutically acceptable carrier per unit dosage.
A typical tablet which may be prepared by conventional tabletting tech¬ niques contains:
Active compound 1.0 mg
Lactosum 67.8 mg Ph.Eur. Avicel® 31.4 mg
Amberlite® IRP 88 1.0 mg
Magnesii stearas 0.25 mg Ph.Eur.
The following examples illustrate the specific methods employed in produc¬ tion of a representative number of compounds embraced by this invention. EXAMPLE 1
4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-[3-(3,4,5-trimethoxyphenylcarbamo- yloxy)propyl]piperidine, oxalate
A. 4-(6-Fluoro-1 ,2-benzisoxazol-3-y I) piperidine, hydrochloride (5.0 g, 20 mmol), 3-bromopropanol (2.0 ml, 21.6 mmol) and potassium carbonate (6.5 g, 47 mmol) in 300 ml dry acetone were refluxed for 16 h. The mixture was cooled to room temperature, filtered and concentrated jn vacuo. The resulting compound was recrystallized from ethanol/water to give 4.3 g of the desired compound. M.p. 139-141 °C.
B. A mixture of 3,4,5-trimethoxyaniline (365 mg; 2.0 mmol) in toluene (20 ml) and phosgene (6 ml 20% in toluene; 12 mmol) was refluxed for 6 h.
The solvent was removed under reduced pressure to give crude 3,4,5- trimethoxyphenylisocyanate. To the crude product was added 3(4-(6-fluoro- 1,2-benzisoxazol-3-yl)-piperidino)propanol (420 mg; 1.5 mmol) in DMF (10 ml). The mixture was stirred at 100°C for 2 h and then at room temperature for 16 h, whereupon it was taken up in ethyl acetate and water. The organic phase was washed with water and saturated sodium chloride and con¬ centrated in vacuo. The resulting oil was taken up in acetone/ethanol (4:1 , v/v) and oxalic acid (150 mg) in 2 ml acetone added to precipitate the desired product. The product was washed with ice cold ethanol giving 550 mg of the title compound. M.p. 77-80°C. MS (70 eV): m/z 487 (9%, M+), 287 (31), 233 (40), 209 (56), 194 (45), 140 (67), 96 (100).
EXAMPLE 2
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1 -[3-(3,4-ethylenedioxyphenylcarbamo- yloxy)propyl]piperidine, oxalate
A mixture of 1 ,4-benzodioxan-6-amine (300 mg; 2.0 mmol) in toluene (20 ml) and phosgene (10 ml 20% in toluene; 19 mmol) was refluxed for 6 h. The solvent was removed under reduced pressure to give crude 3,4- ethylenedioxyphenylisocyanate. To the crude product was added 3-[4-(6- fluoro-1 ,2-benzisoxazol-3-yl)piperidino]propanol (420 mg; 1.5 mmol) in DMF (10 ml). The mixture was stirred at 100°C for 2 h and then at room tempera¬ ture for 16 h, whereupon it was taken up in ethyl acetate and water. The organic phase was washed with water and saturated sodium chloride and concentrated in vacuo. The resulting oil was taken up in acetone/ethanol (4:1 , v/v) and oxalic acid (150 mg) in 2 ml acetone added to precipitate the desired product. The product was washed with ice cold ethanol to give 600 mg of the title compound. M.p. 109-110°C. MS (70 eV): m/z 455 (32%, M+), 278 (23), 233 (49), 177 (89), 140 (48), 121 (42), 96 (100).
EXAMPLE 3
1-[3-(6-Benzothiazolylcarbamoyloxy)propyl]-4-(6-fluoro-1 ,2-benzisoxazol-3- yl) piperidine, oxalate
A mixture of 6-aminobenzothiazole (300 mg; 2 mmol) in toluene (20 ml) and phosgene (10 ml 20% in toluene, 19 mmol) was refluxed for 6 h. The solvent was removed under reduced pressure to give crude 6-benzothiazo- lylisocyanate. Using the procedure of example 1 the crude 6-benzothiazolyl- isocyanate was combined with 3-[4-(6-fluoro-1 ,2-benzisoxazol-3-yl)-piperi- dino]propanol (410 mg; 1.5 mmol) in 10 ml DMF to give the 0.7 g of the title compound. M.p. 176-177°C. MS (70 eV): m/z 454 (3%, M+), 27 (25), 233 (30), 190 (17), 176 (55), 150 (37), 140 (53), 96 (100).
EXAMPLE 4
1-[3-(3,4-Ethylenedioxyphenylthiocarbamoyloxy)propyl]-4-(6-fluoro-1 ,2- benzisoxazol-3-yl)ρiperidine, oxalate To a mixture of 1 ,4-benzodioxan-6-amine (15.1 g; 100 mmol) and triethyl- amine (20.2 g; 200 mmol) in toluene (350 ml) was added dropwise over 10 min. thiophosgeπe (11.5 g; 100 mmol) in toluene (50 ml). The mixture was stirred at 80°C for 30 min., cooled to room temperature and filtered. The filtrate was evaporated. The product was redissolved in toluene and con¬ centrated in vacuo. The resulting oil was taken up in warm petroleum ether, which was filtered. The filtrate was concentrated to a small volume, which afforded 7.2 g of 3,4-ethylenedioxyphenylisothiocyanate.
Starting from 3,4-ethylenedioxyphenylisothiocyanate (390 mg; 2.0 mmol) and 3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]propanol (420 mg; 1.5 mmol) using the procedure described in example 1 was prepared 550 mg of the title compound: M.p. 101-104°C. MS (70 eV): m/z 471 (0.5%, M+), 278 (61), 233 (58), 193 (100), 151 (17), 140 (60).
EXAMPLE 5
4-(6-FIuoro-1 ,2-benzisoxazol-3-yl)-1-[2-(3,4,5-trimethoxyphenylcarbamoyl- oxy)ethyl]piperidine, oxalate
A. 4-(6-Fluoro-1 ,2-benzisoxazoI-3-yl)piperidine, hydrochloride (2.6 g, 10 mmol), 2-bromoethanol (1.3 ml, 15 mmol) and potassium carbonate (4.1 g, 30 mmol) in 25 ml dry acetone were refluxed for two hours and then stirred at 60°C for 16 h, whereupon extra 0.4 ml (5 mmol) 2-bromoethanol was added. The mixture was then refluxed for 4 h, cooled to room temperature, concentrated |n vacuo and taken up in water and methylene chloride. The organic phase was washed with water and saturated sodium chloride, dried over MgS04 and concentrated in vacuo. Purification by column chromato- graphy (silica gel; methylene chloride:methanol:conc. ammonium hydroxide (80:20:0.5, v/v/v)) gave 2.2 g of 2-[4(6-fluoro-1,2-benzisoxazol-3-yl)piperidi- no] ethanol. M.p. 119-120°C. B. Starting from 3,4,5-trimethoxyphenylisocyanate (600 mg, 3 mmol) and 2-[4-(6-fluoro-1 ,2-benzisoxazol-3-yl)-piperidino]ethanol (400 mg; 1.5 mmol) using the procedure described in example 1 was prepared 450 mg of the title compound. M.p. 158-160°C. MS (70 eV): m/z 473 (32%, M+), 246 (38), 233 (100), 209 (41).
EXAMPLE 6
1-(3-(6-Benzthiazolylthiocarbamoyloxy)propyl)-4-(6-fluoro-1 ,2-benzisoxazol-3- yl)piperidine, oxalate
Using the procedure described in example 4 starting from 3-[4-(6-fluoro-1 ,2- benzisoxazol-3-yl)piperidino]propanol (280 mg, 1.0 mmol) and 6-benzothia- zolylisothiocyanate (210 mg, 1.2 mmol), prepared from 6-aminobenzothiazo¬ le and thiophosgene, was prepared 280 mg of the title compound. M.p. 108-112°C, MS (70 eV): m/z 470 (0.2%, M+), 278, (38), 233 (30), 192 (62), 150 (65), 140 (75), 96 (100).
EXAMPLE 7
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1-(3-(3,4-methylenedioxyphenylcarbamoyl- oxy)propyl)piperidine, oxalate
Using the procedure described in example 1 starting from 3-[4-(6-fluoro-1 ,2- benzisoxazol-3-yl)piperidino]propanol (140 mg, 0.5 mmol) and 3,4-methyl- enedioxyphenylisocyanate (240 mg, 1.5 mmol), prepared from 3,4-methyl- enedioxyaniline and phosgene, was prepared 210 mg of the title com- pound. M.p. 133-136°C. MS (70 eV): m/z 441 (20%, M+), 303 (15), 278 (16),
233 (53), 163 (52), 140 (37), 96 (100). EXAMPLE 8
1-[2-(6-Benzothiazolylcarbamoyloxy)ethyl]-4-(6-fluoro-1,2-benzisoxazol-3- y I) piperidine, oxalate
Using the procedure of example 3 crude 6-benzothiazolylisocyanate, pre¬ pared from 6-aminobenzothiazole (500 mg, 3.4 mmol), was combined with 2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]ethanol (450 mg, 1.7 mmol) in 10 ml dry DMF to give 100 mg of the title compound. M.p. 130-134°C. MS (70 eV): m/z 440 (1%, M+), 264 (23), 233 (69), 150 (100).
EXAMPLE 9
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1 -[2-(3,4-methyleπedioxyphenylcarbamoyl- oxy)ethyl]piperidine, hydrochloride
Starting from 3,4-methylenedioxyphenylisocyanate (320 mg, 2 mmol) and 2- [4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]ethanol (270 mg, 1 mmol) in 5 ml dry DMF using the procedure described in example 1 was prepared 210 mg of the title compound as free base. This product was dissolved in 5 ml ethanol/acetone (50%, v/v) and ethanolic hydrochloric acid added to precipitate 180 mg of the desired product as white crystals. M.p. 226-229°C. MS (70 eV): m/z 428 (47%, M+), 246 (42), 233 (100), 208 (21), 190 (47), 163 (70).
EXAMPLE 10
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1 - [3-(pheny Icarbamoy loxy) propyl] piperidi¬ ne, hydrochloride
Phenylisocyanate (0.36 g, 3 mmol) and 3-[4-(6-fluoro-1 ,2-benzisoxazol-3- yl)piperidino]propanol (0.3 g, 1.1 mmol) was refluxed in toluene (25 ml) for 6 h. The mixture was cooled to room temperature and hydrochloric acid in ether was added. The resulting precipitate was recrystallized from etha- nol/ether and isopropanol/ether to give 180 mg of the title compound as white crystals. M.p. 204.5-205.5°C. MS (70 eV): m/z 397 (39%, M+), 278 (4), 259 (26), 233 (50), 178 (28), 96 (100).
EXAMPLE 11
N-Cyano-N'-(3,4-methylenedioxyphenyl)-N"-3-((6-fluoro-1 ,2-benzisoxazol-3- yl)piperidino)propyl)guanidine, oxalate
A mixture of N-cyanodiphenoxyimidocarbonate (1.2 g, 5 mmol), 3,4-methy- lenedioxyaniline (0.7 g, 5 mmol) and 2-propanol (25 ml) was stirred at room temperature for 16 h. The formed precipitate was taken up in methylene chloride, treated with activated carbon. Evaporation of the solute and trituration with ether gave 1.2 g of N-cyano-N'-3,4-methylenedioxyphenyl-0- phenylisourea. M.p. 172-174°C.
1-(3-Aminopropyl)-4-(6-fluoro-1 ,2-benzisoxazol-3-yl) piperidine (420 mg, 1.1 mmol), N-cyano-N'-3,4-methylenedioxyphenyl-0-phenylisourea (320 mg, 1.2 mmol), 0.4 ml triethyl amine and 25 ml 2-propanol were stirred at room temperature for 4 days. The mixture was concentrated in vacuo and then taken up in water and methylene chloride. The organic phase was washed with water and saturated sodium chloride, dried over magnesium sulphate and concentrated jπ vacuo. The product was purified by column chroma¬ tography (silica gel; ethyl acetate:methanol (4:1 , v/v)), and then taken up in 2 ml dry acetone. Oxalic acid (50 mg) in 1 ml acetone was added precipi¬ tating 90 mg of the desired product as white crystals. M.p. 112-115°C. MS (70 eV): m/z 464 (M+, 1%), 422 (4), 233 (10), 220 (32), 137 (100). EXAMPLE 12
1-[3-(3,4-Methylenedioxyphenylcarbamoyloxy)propyl]-4-(6-fluoro-1H-indazol-
3-yl) piperidine
A. To a mixture of 6-fluoro-3-(4-piperidinyl)-1 H-indazole (438 mg, 2 mmol) and dry potassium carbonate (1.1 g, 6 mmol) in 30 ml methyl isobutyl ketone was added 3-bromo-1-propanol (276 mg, 2 mmol). The mixture was refluxed for 48 h, cooled, filtered and concentrated |n vacuo. The crude product was purified by chromatography on silica gel 60 eluting with ethyl acetate:methanol (9:1 , v/v). Concentration of the appropriate fractions afforded 300 mg (53%) of 3-[l-(1-hydroxyprop-3-yl)-4-piperidinyl]- 6-fluoro-1 H-indazole as an oil.
1H-NMR (DMSO-d6, s): 1.62 (t, 2H), 1.7-2.1 (br., 8H), 2.39 (t, 2H), 2.95 (br., 3H), 3.48 (t, 2H), 6.90 (dt, 1H), 7.21 (dd, 1H), 7.78 (q, 1H), 12.70 (s, 1H).
B. A solution of 3-[1-(1 -hydroxyprop-3-yl)-4-piperidinyl]-6-fluoro-1 H- indazole (230 mg, 0.83 mmol) in 5 ml dry DMF was added 3,4-methylenedi- oxyphenylisocyanate (291 mg, 1.65 mmol) in 3 ml dry DMF. The reaction was heated to 100°C for 2 h and 16 h at 80°C. The reaction was cooled to room temperature and added a mixture of 50 ml water and 200 ml ether, filtered and separated. The ether phase was washed with water, brine and dried with sodium sulphate and concentrated in, vacuo. The crude product was purified by chromatography on silica gel 60 eluting with ethyl acetate:methanol (9:1 , v/v). Concentration of the appropriate fractions afforded 50 mg (11 %) of the title compound as an amorphous solid.
1H-NMR (DMSO-d6, δ): 1.71-1.92 (m, 6H), 2.1 (m, 2H), 2.42 (br., 2H), 2.98 (br.d, 3H), 4.11 (t, 2H), 5.95 (s, 2H), 6.82 (m, 2H), 6.91 (t, 1H), 7.14 (s, 1H), 7.21 (dd, 1H), 7.80 (dt, 1 H), 9.5 (sr 1H), 12.68 (s, 1H). Analysis: C23H25N404F, 0.75 H20: Calculated: C 60.85; H 5.88; N 12.34%
Found: C 60.69; H 5.76; N 12.31 %
MS (70 eV): m/z 440 (M+, 1%), 277 (14), 232 (100), 218 (12), 189 (37), 163
(80), 70 (16).
EXAMPLE 13
1 -[2-(3,4-Methylenedioxyphenylcarbamoyloxy)propyl]-4(6-fluoro-1 H-indazol- 3-yl)piperidine
A. A mixture of 6-fluoro-3-(4-piperidinyl)-1 H-indazole (500 mg, 2.3 mmol) and propylene oxide (1 g, 17 mmol) in 25 ml toluene was heated to 50°C in an autoclave for 7 days. The cooled reaction was concentrated jn vacuo and purified by chromatography on silica gel 60 eluting with ethyl acetate :methanol (4:1 , v/v). Concentration of the appropriate fractions afforded 350 mg (54.9%) of 3-[1-(2-hydroxyρrop-1-yl)-4-piperidinyl]-6-fluoro- 1 H-indazole as a foam.
1H-NMR (DMSO-d6, δ): 1.04 (d, 3H), 1.87 (m, 4H), 2.18 (m, 4H), 2.93 (br. d, 3H), 3.78 (m, 1 H), 4.25 (br., 1 H), 6.91 (dt, 1 H), 7.20 (dd, 1 H), 7.78 (q, 1 H), 12.58 (s, 1 H).
B. Starting from 3-[1 -(2-hydroxyprop-1 -yl)-4-piperidinyl]-6-fluoro-1 H- indazole (300 mg, 1.1 mmol) and 3,4-methylenedioxyphenylisocyanate (380 mg, 2.2 mmol) using the procedure described in example 12A was pre¬ pared 40 mg (9%) of the title compound as an amorphous solid.
1H-NMR (DMSO-d6, δ): 1.21 (d, 3H), 1.85 (m, 4H), 2.20 (m. 2H), 2.4 (m, 1 H), 2.55 (m, 1 H), 3.0 (m, 2H), 3.1 (m, 1 H), 4.9 (m, 1 H), 5.98 (s, 2H), 6.8 (d, 1 H), 6.89 (m,2H), 7.14 (s, 1 H), 7.19 (dd, 1 H), 7.73 (dt, 1 H), 9.51 (s, 1 H), 12.68 (s, 1H).
MS (70eV): m/z 441 (M++, 1.1%), 440 (M+, 1), 259 (29), 232 (100), 218 (7), 189 (48), 163 (41), 137 (15).
EXAMPLE 14
1-[6-(3,4-MethyIenedioxyphenylcarbamoyloxy)hexyl]-4-(6-fluoro-1,2-beπzis- oxazol-3-y I) piperidine
A. A mixture of 6-fluoro-3-(4-piperidinyl)-1 ,2-benzisoxazole hydrochloride (1 g, 3.9 mmol), lithium carbonate (865 mg, 1.7 mmol) and 6- chloro-1-hexaπol (534 mg, 3.9 mmol) in 5 ml dry DMF was heated at 100°C for 48 h. The reaction was poured into water and the aqueous mixture was extracted with ethyl acetate. The ethyl acetate phase was washed with water, brine, dried with sodium sulphate and concentrated in vacuo. The crude product was purified by chromatography on silica gel 60 eluting with ethyl acetate:methanol (9:1 , v/v). Concentration of the appropriate fractions afforded 310 mg (25.6%) of 3-[1-(1-hydroxyhex-6-yl)-4-piperidinyl]-6-fluoro- 1 ,2-benzisoxazole as an oil.
1H-NMR (CDCI3. δ): 1.39 (m, 4H), 1.58 (m, 4H), 2.10 (m, 6H), 2.41 (t, 2H), 3.09 (br.d, 3H), 3.65 (t, 2H), 7.04 (dt, 1H), 7.23 (dd, 1H), 7.75 (q, 1H).
MS (70 eV): m/z 320 (M+, 28%), 233 (47), 190 (15), 182 (50), 96 (100), 82 (100), 82 (21), 55 (23).
B. Starting from 3-[1 -(1 -hydroxyhex-6-yl]-4-piperidinyl]-6-fluoro-1 ,2- benzisoxazole (270 mg, 0.84 mmol) and 3,4-methylenedioxyphenylisocya- nate (297 mg, 1.69 mmol) using the procedure described in example 12B was prepared 210 mg (51.8%) of the title compound as an amorphous solid. 1H-NMR (CDCI3, δ): 1.4 (m, 4H), 1.6 (m, 4H), 2.11 (m, 6H), 2.42 (t, 2H), 3.09 (br.d, 3H), 4.15 (t, 2H), 5.95 (s, 2H), 6.70 (m, 2H), 7.05 (m, 2H), 7.24 (m, 2H), 7.72 (q, 1 H).
MS (70 eV): m/z 483 (M+, 1.5%), 320 (22), 233 (45), 182 (32), 163 (100), 130 (75), 96 (70), 77 (35).
EXAMPLE 15
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1 -(3-(2-bromo-4,5-methylenedioxyphenyi- carbamoyloxy)propyl)piperidine, hydrochloride
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1-(3-(3,4-methylenedioxyphenylcarbamoyl- oxy)propyl)piperidine (example 7) (220 mg, 0.5 mmol) was dissolved in 2 ml glacial acetic acid and the mixture stirred at room temperature under N2. Br2 (0.25 μl, 0.5 mmol) dissolved in 1.0 ml glacial acetic acid was added. The mixture was stirred for 2 h whereupon aqueous r jCOg was added to neutralize the solution, which was then extracted with ethyl acetate. The organic phase was dried over magnesium sulphate and concentrated in vacuo. The product was taken up in acetone and HCI in ether added to crystallize the desired product as 40 mg white crystals. M.p. 215-218°C. MS (70 eV): m/z 521 (17%, M+), 519 (17%, M+), 278 (20), 243 (35), 241 (34), 233 (56), 96 (100).
EXAMPLE 16
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1-(3-(3,4-methylenedioxyphenylthiocarba- moyloxy)propyl)piperidine, hydrochloride
3,4-Methylenedioxyphenylisothiocyanate (360 mg, 2 mmol) and 3-[4-(6- fluoro-1 ,2-benzisoxazol-3-yl)piperidino]propanol (4.20 mg, 1.5 mmol) in 5 ml dry DMF were stirred at 100°C for 2 h and then at 60°C for 16 h. The mixture was cooled to room temperature and taken up between water and ether. The organic phase was washed with water and saturated sodium chloride, dried over magnesium sulphate and concentrated in vacuo. Purification of the product by column chromatography (silicagel; ethyl acetate:methanol (4:1 , v/v)) gave an oil, which was taken up in dry acetone. HCI in ether was added to crystallize the desired product as 550 mg white crystals. M.p. 181-185°C. MS (70 eV): m/z 457 (1%, M+), 278 (55), 233 (56), 179 (100).
EXAMPLE 17
4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-(3-(2-methoxyphenyl)carbamoyloxy)- propyl) piperidine, hydrochloride
2-Methoxyphenylisocyanate (270 mg, 2 mmol) and 3-[4-(6-fluoro-1 ,2-benz- isoxazol-3-yl)piperidino]propanol (280 mg, 1 mmol) was dissolved in 100 ml dry toluene and refluxed for 16 h. 50 ml ethyl acetate was added to the cooled mixture, which was then washed with water and saturated sodium chloride. 2.5 ml (1.9 M) HCI in ethanol was added and the solution was concentrated to about 30 ml crystallizing 310 mg of the desired product. M.p. 174-175°C. MS (70 eV): m/z 427 (30%, M+), 289 (19), 233 (33), 96 (100).
EXAMPLE 18
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1-(3-(3-chloro-4-methoxyphenyl)carbamo- yloxy)propyl, hydrochloride
Starting from 3-chloro-4-methoxyphenylisocyanate, prepared from 3-chloro- 4-methoxyaniline (470 mg, 3 mmol) and phosgene (7.5 mmol) as described in example 1, and 3-[4-(6-fluoro-1;2-benzisoxazol-3-yl)piperidino]propanol (560 mg, 2 mmol) using the procedure of example 1 , was prepared 500 mg mg of the desired product. M.p. 212-215°C.
EXAMPLE 19
1 -[2-(3,4-Methylenedioxyphenylcarbamoyloxy)propyl]-4-(6-fluoro-1 ,2-benz- isoxazol-3-yl) piperidine, oxalate
A. A mixture of 6-fluoro-3-(4-piperidinyl)-1 ,2-benzisoxazol (1.5 g, 6.8 mmol) and propylene oxide (2 g, 34.4 mmol) in 25 ml acetonitrile was heated to 50°C in an autoclave for 3 days. The cooled reaction was con¬ centrated jn vacuo and purified by chromatography on silica gel 60 eluting with ethyl acetate:methanol (9:1 , v/v). Concentration of the appropriate fraction afforded 1.3 g (68.4%) of 3-[1-(2-hydroxyproρ-1-yl)-4-piperidinyl]-6- fluoro-1 ,2-benzisoxazole. M.p. 45-47°C. MS (70 eV): m/z 278 (M+, 18%), 233 (100), 190 (28), 109 (12), 96 (70), 82 (25), 68 (14), 55 (22).
B. Starting from 3-[1 -(2-hydroxyprop-1 -yl)-4-piperidinyl]-6-fluoro-1 ,2- benzisoxazole (500 mg, 1.1 mmol) and 3,4-methylenedioxyphenyIisocyanate (500 mg, 2.2 mmol) using the procedure described in example 12B was prepared 100 mg (17%) of the title compound. M.p. 163-164°C. MS (70 eV): m/z 441 (M+, 11%), 260 (32), 233 (100), 190 (25), 163 (17), 136 (33), 96 (58).
Analysis: C25H26N3F09, 0.5 H20
Calculated: C 55.55; H 5.03; N 7.77%
Found: C 55.74; H 4.91 ; N 7.39%

Claims

t. A compound of formula I
Figure imgf000036_0001
wherein A represents a straight or branched saturated hydrocarbon chain containing from 2 to 6 carbon atoms;
R1 is
Figure imgf000036_0002
wherein R3, R4, R5 and R6 independently are hydrogen, halogen or C1-6- alkyl;
B is -O- or -NH-;
X is -0- or -NH-
Y is =0, =S or =NZ
wherein Z is hydrogen, C-^-alkyl or -CN; R2 is selected from the group consisting of
Figure imgf000037_0001
wherein R7, R8, R9 and R10 independently are hydrogen, C^-alkyl, halogen, C^-alkoxy or perhalomethyl;
-D- represents a 5- or 6-membered heterocycle containing one or more N-, 0- or S-atoms, or a pharmaceutically acceptable salt thereof.
The compound according to claim 1 which is
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1-[3-(3,4,5-trimethoxyphenylcarbamo- yloxy) propy I] piperidine;
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1 -[3-(3,4-ethylenedioxyphenylcarbamo- yloxy) propyl] piperidine ;
1-[3-(6-Benzothiazolylcarbamoyloxy)propyl]-4-(6-fluoro-1 ,2-benzisoxazol-3- yl)piperidine;
1-[3-(3,4-Ethylenedioxyphenylthiocarbamoyloxy)propyl]-4-(6-fluoro-1 ,2- benzisoxazol-3-yl) piperidine ;
4-(6-Fluoro-1 ,2-benzisoxazol-3-y.)-1-[2-(3,4,5-trimethoxyphenylcarbamoyl- oxy)ethyl]piperidine;
1-(3-(6-Benzthiazolylthiocarbamoyloxy)propyl)-4-(6-fluoro-1 ,2-benzisoxazol-3- y piperidine;
4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-(3-(3,4-methylenedioxyphenylcarbamoyl- oxy)propyl)piperidine;
1-[2-(6-Benzothiazolylcarbamoyloxy)ethyl]-4-(6-fluoro-1,2-benzisoxazol-3- yl)piperidine;
4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-[2-(3,4-methyfenedioxyphenylcarbamoyl- oxy)ethyl]piperidine;
4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-[3-(phenylcarbamoyloxy)propyl] piperi¬ dine;
N-Cyano-N'-(3,4-methylenedioxyphenyl)-N,r-3-((6-fluoro-1 ,2-benzisoxazol-3- yl)piperidino)propyl)guanidine;
1-[3-(3,4-Methylenedioxyphenylcarbamoyloxy)propyl]-4-(6-fluoro-1H-indazoI- 3-yl)piperidine;
1-[2-(3,4-MethylenedioxyphenyIcarbamoyloxy) propyi] -4-(6-fluoro-1H-indazol- 3-yl) piperidine;
1-[6-(3,4-Methylenedioxyphenylcarbamoyloxy)hexyl]-4-(6-fluoro-1,2-benz- isoxazol-3-yl)piperidine;
4-(6-(Fluoro-1,2-benzisoxazol-3-yl)-1-(3-(2-bromo-4,5-methylenedioxyphenyl- carbamoyloxy) propyi) piperidine ;
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1 -(3-(3,4-methylenedioxyphenylthiocarba- moyloxy) propyi) piperidine; 4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1-(3-(2-methoxyphenyl)carbamoyloxy)pro- pyl)piperidine;
4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1-(3-(3-chloro-4-methoxyphenyl)carbamo- yloxy) propyi;
1-[2-(3,4-Methylenedioxyphenylcarbamoyloxy)propyl]-4-(6-fluoro-1 ,2-benz- isoxazol-3-yl)piperidine;
or a pharmaceutically acceptable salt thereof.
3_, A method of preparing a compound according to claim 1 , which comprises
a) reacting a compound of formula II
γ=C=N-R2 (II)
wherein Y and R2 have the meanings set forth above, with a compound of formula III
Figure imgf000039_0001
wherein A, X and R1 have the meanings set forth above , or
b) reacting a compound of formula IV (IV)
Figure imgf000040_0001
wherein A and R1 have the meanings set forth above, with a compound of formula V
Figure imgf000040_0002
wherein R2 and Z have the meanings set forth above, or
* c) reacting a compound of formula VI
Figure imgf000040_0003
prepared from a compound of formula VII
Figure imgf000040_0004
wherein A, R and R2 have the meanings set forth above and W is 0 or S, with NH2-Z, wherein Z has the meaning set forth above, to form a com¬ pound of formula I, or
d) reacting a compound of formula III, wherein X is -NH- and A and R1 have the meanings set forth above, with a compound of formula VIII
Figure imgf000041_0001
wherein R2 has the meaning set forth above to form a compound of formula I wherein X is -NH-.
__ A pharmaceutical composition comprising as active component a compound according to claim 1 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
5__ A pharmaceutical composition suitable for use in the treatment of psychosis, which comprises as active component a compound according to claim 1 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
6. The pharmaceutical composition according to claim 4 or 5 in the form of an oral dosage unit containing about 10-200 mg of the active compound.
7. A method of treating psychosis in a subject in need thereof com- prising administering an effective amount of a compound according to claim 1. 8. A method of treating psychosis in a subject in need thereof com¬ prising administering a pharmaceutical composition according to claim 5.
9. Use of a compound according to claim 1 or 2 for the preparation of a medicament for the treatment of psychosis.
PCT/DK1992/000348 1991-11-27 1992-11-25 Chemical compounds, their preparation and use WO1993010742A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP5509722A JPH07502268A (en) 1991-11-27 1992-11-25 Chemical compounds, their preparation and use
EP92924586A EP0679085A1 (en) 1991-11-27 1992-11-25 Chemical compounds, their preparation and use
AU30817/92A AU672182B2 (en) 1991-11-27 1992-11-25 Piperidine derivatives and their use in treating psychosis
NO941965A NO300684B1 (en) 1991-11-27 1994-05-26 Piperidine Compounds, Pharmaceutical Preparations Containing Them, and Use of the Compounds for the Preparation of a Medication for the Treatment of Psychosis
FI942468A FI942468A (en) 1991-11-27 1994-05-26 Chemical compounds, their preparation and use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPCT/DK91/00354 1991-11-27
DK9100354 1991-11-27
DK71092A DK71092D0 (en) 1992-05-27 1992-05-27 CHEMICAL COMPOUNDS, THEIR PREPARATION AND USE
DK0710/92 1992-05-27

Publications (2)

Publication Number Publication Date
WO1993010742A2 true WO1993010742A2 (en) 1993-06-10
WO1993010742A3 WO1993010742A3 (en) 1993-07-22

Family

ID=26064501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1992/000348 WO1993010742A2 (en) 1991-11-27 1992-11-25 Chemical compounds, their preparation and use

Country Status (4)

Country Link
JP (1) JPH07502268A (en)
AU (1) AU672182B2 (en)
NZ (1) NZ245260A (en)
WO (1) WO1993010742A2 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027994A1 (en) * 1993-05-26 1994-12-08 Novo Nordisk A/S Piperidine derivatives, their preparation and use
US5441966A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting Turner's syndrome
US5461064A (en) * 1993-12-21 1995-10-24 Eli Lilly And Company Methods of inhibiting atrophy of the skin and vagina
US5476862A (en) * 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
US5482950A (en) * 1993-10-15 1996-01-09 Eli Lilly And Company Methods for lowering serum cholesterol
US5488058A (en) * 1995-02-28 1996-01-30 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and method for inhibiting restenosis
US5504094A (en) * 1994-10-20 1996-04-02 Eli Lilly And Company Use of bengothiophenls to treat pain due to an excess of neuropeptide y
WO1996021660A1 (en) * 1995-01-12 1996-07-18 Merck Sharp & Dohme Limited Five-membered heteroaromatic compounds as dopamine receptor subtype ligands
US5567712A (en) * 1995-02-28 1996-10-22 Eli Lilly And Company Naphthyl compounds, intermediates, compositions and methods
US5708010A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
US5856339A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
US5919800A (en) * 1995-02-28 1999-07-06 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5977093A (en) * 1995-02-28 1999-11-02 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5998441A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
FR2821356A1 (en) * 2001-02-23 2002-08-30 Cerep NOVEL ARYLCARBAMATE AND ARYLUREES DERIVATIVES, PREPARATIONS AND USES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368388A2 (en) * 1988-11-07 1990-05-16 Janssen Pharmaceutica N.V. 3-Piperidinyl-1,2-benzisoxazoles
EP0377528A1 (en) * 1989-01-05 1990-07-11 Lipha, Lyonnaise Industrielle Pharmaceutique Piperidines, process for their preparation and pharmaceutical compounds containing them
EP0402644A1 (en) * 1989-05-19 1990-12-19 Hoechst-Roussel Pharmaceuticals Incorporated N-(aryloxyalkyl)heteroarylpiperidines and -heteroarylpiperazines,a process for their preparation and their use as medicaments
EP0428437A1 (en) * 1989-11-07 1991-05-22 Adir Et Compagnie 1,2-Benzisoxazole derivatives, process for their preparation and pharmaceutical compositions containing them

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368388A2 (en) * 1988-11-07 1990-05-16 Janssen Pharmaceutica N.V. 3-Piperidinyl-1,2-benzisoxazoles
EP0377528A1 (en) * 1989-01-05 1990-07-11 Lipha, Lyonnaise Industrielle Pharmaceutique Piperidines, process for their preparation and pharmaceutical compounds containing them
EP0402644A1 (en) * 1989-05-19 1990-12-19 Hoechst-Roussel Pharmaceuticals Incorporated N-(aryloxyalkyl)heteroarylpiperidines and -heteroarylpiperazines,a process for their preparation and their use as medicaments
EP0428437A1 (en) * 1989-11-07 1991-05-22 Adir Et Compagnie 1,2-Benzisoxazole derivatives, process for their preparation and pharmaceutical compositions containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Med. Chem., Volume 29, 1986, JOSEPH P. YEVICH et al., "Synthesis and Biological Evaluation of 1-(1,2-Benzisothiazol-3-yl)- and (1,2-Benzisoxazol-3-yl)piperazine Derivatives as Potential Antipsychotic Agents", see page 359. *

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478845A (en) * 1993-05-26 1995-12-26 Novo Nordisk A/S Piperidine derivatives
WO1994027994A1 (en) * 1993-05-26 1994-12-08 Novo Nordisk A/S Piperidine derivatives, their preparation and use
US5521172A (en) * 1993-10-15 1996-05-28 Eli Lilly And Company Methods for lowering serum cholesterol
US5552433A (en) * 1993-10-15 1996-09-03 Eli Lilly And Company Method for lowering serum cholesterol
US5556876A (en) * 1993-10-15 1996-09-17 Eli Lilly And Company Methods for lowering serum cholesterol
US5482950A (en) * 1993-10-15 1996-01-09 Eli Lilly And Company Methods for lowering serum cholesterol
US5441966A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting Turner's syndrome
US5476862A (en) * 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
US5708009A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
US5708010A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
US5700815A (en) * 1993-12-21 1997-12-23 Eli Lilly And Company Methods of increasing thrombomodulin expression
US5698572A (en) * 1993-12-21 1997-12-16 Eli Lilly And Company Methods of inhibiting turner's syndrome
US5461064A (en) * 1993-12-21 1995-10-24 Eli Lilly And Company Methods of inhibiting atrophy of the skin and vagina
US5610167A (en) * 1993-12-21 1997-03-11 Eli Lilly And Company Methods of inhibiting atrophy of the skin and vagina
US5504094A (en) * 1994-10-20 1996-04-02 Eli Lilly And Company Use of bengothiophenls to treat pain due to an excess of neuropeptide y
US5576337A (en) * 1994-10-20 1996-11-19 Eli Lilly And Company Method of treating anxiety by inhibiting physiological conditions associated with an excess of neuropeptide Y
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5567715A (en) * 1994-10-20 1996-10-22 Eli Lilly And Company Methods of treating depression by inhibiting physiological conditions associated with an excess of neuropeptide Y
US5567714A (en) * 1994-10-20 1996-10-22 Eli Lilly And Company Methods of treating obesity by inhibiting physiological conditions associated with an excess of neuropeptide Y
US5939436A (en) * 1995-01-12 1999-08-17 Merck Sharp & Dohme Ltd. Five-membered heteroaromatic compounds as dopamine receptor subtype ligands
WO1996021660A1 (en) * 1995-01-12 1996-07-18 Merck Sharp & Dohme Limited Five-membered heteroaromatic compounds as dopamine receptor subtype ligands
US5492922A (en) * 1995-02-28 1996-02-20 Eli Lilly And Company Benzothiophene compounds intermediate compositions and methods for inhibiting aortal smooth muscle proliferation
US6268361B1 (en) 1995-02-28 2001-07-31 Alan D. Palkowitz Naphthyl compounds, intermediates, compositions, and methods
US5919800A (en) * 1995-02-28 1999-07-06 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5510358A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and method of treating endomethiosis
US5723474A (en) * 1995-02-28 1998-03-03 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5856339A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
US5510498A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5574190A (en) * 1995-02-28 1996-11-12 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5977093A (en) * 1995-02-28 1999-11-02 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5998441A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5567712A (en) * 1995-02-28 1996-10-22 Eli Lilly And Company Naphthyl compounds, intermediates, compositions and methods
US5488058A (en) * 1995-02-28 1996-01-30 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and method for inhibiting restenosis
WO2002068399A1 (en) * 2001-02-23 2002-09-06 Cerep Aryl carbamate derivatives, preparation and use thereof
FR2821356A1 (en) * 2001-02-23 2002-08-30 Cerep NOVEL ARYLCARBAMATE AND ARYLUREES DERIVATIVES, PREPARATIONS AND USES
US7238693B2 (en) 2001-02-23 2007-07-03 Cerep Aryl carbamate derivatives, preparation and use thereof
AU2002238688B2 (en) * 2001-02-23 2007-07-26 Cerep Aryl carbamate derivatives, preparation and use thereof

Also Published As

Publication number Publication date
AU3081792A (en) 1993-06-28
JPH07502268A (en) 1995-03-09
NZ245260A (en) 1995-06-27
WO1993010742A3 (en) 1993-07-22
AU672182B2 (en) 1996-09-26

Similar Documents

Publication Publication Date Title
EP0544765B1 (en) Piperazinyl derivatives with affinity for 5-HT receptors
EP0544756B1 (en) 1,2,5,6-tetrahydro-1-methylpyridines, their preparation and use
US6288068B1 (en) Muscarinic antagonists
US5017573A (en) Indazole-3-carboxylic acid derivatives
DE69922186T2 (en) 1- (1-SUBST.-4-PIPERIDINYL) METHYL] -4-PIPERIDINE DERIVATIVES, PROGRAMS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL MIXTURES AND INTERMEDIATES FOR THE PREPARATION THEREOF
EP1318811B1 (en) Cyclopentyl modulators of chemokine receptor activity
WO1993010742A2 (en) Chemical compounds, their preparation and use
NZ209279A (en) 3-(piperidinyl)- and 3-(pyrrolidinyl)-1h-indazole derivatives and pharmaceutical compositions
CA2937147A1 (en) Substituted amino triazoles, and methods using same
AU2003284165A1 (en) Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity
HU195640B (en) Process for producing 2-/4-benzoyl-1-piperidinyl/-1-phenyl-alkanol derivatives and pharmaceutical compositions containing them
WO2004041163A2 (en) Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity
US5391549A (en) Cinnoline-3-carboxylic acid derivatives
EP2313394A1 (en) Novel tetramethyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO1994027991A1 (en) Piperidine derivatives, their preparation and use
US5478845A (en) Piperidine derivatives
US5378714A (en) Antipsychotic piperidine derivatives
US5525600A (en) (Thiophen-2-yl)-piperidin or tetrahydropyridin carboxamides
US20040259914A1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP0679085A1 (en) Chemical compounds, their preparation and use
US6750231B2 (en) 4-arylpiperidine derivatives for the treatment of pruritus
US5166341A (en) 6-amino-1,4-hexahydro-1H-diazepine derivatives
EP0700398B1 (en) Psoralen derivatives, their preparation and use as medicaments
WO1994027996A1 (en) 1,2,5-thiadiazole derivatives, their preparation and use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BG CA CS FI HU JP KR NO PL PT RO RU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BG CA CS FI HU JP KR NO PL PT RO RU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page

Free format text: REVISED ABSTRACT RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1992924586

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2117304

Country of ref document: CA

Ref document number: 942468

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1992924586

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992924586

Country of ref document: EP